Details for New Drug Application (NDA): 021883
✉ Email this page to a colleague
The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the dalbavancin hydrochloride profile page.
Summary for 021883
Tradename: | DALVANCE |
Applicant: | Abbvie |
Ingredient: | dalbavancin hydrochloride |
Patents: | 1 |
Suppliers and Packaging for NDA: 021883
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883 | NDA | Allergan, Inc. | 57970-100 | 57970-100-01 | 1 VIAL in 1 PACKAGE (57970-100-01) / 25 mL in 1 VIAL |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 500MG BASE/VIAL | ||||
Approval Date: | May 23, 2014 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 23, 2024 | ||||||||
Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
Regulatory Exclusivity Expiration: | May 23, 2019 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Regulatory Exclusivity Expiration: | Jul 22, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PATIENT POPULATION |
Expired US Patents for NDA 021883
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription